Table 2.

Univariate Analysis of Overall Survival

Variable	Categories	HR (95% CI)	P Value
Anticoagulation use	Yes versus no	0.61 (0.40-0.94)	.024
LMWH	Yes versus no anticoagulation	0.58 (0.34-0.99)	.048
Warfarin	Yes versus no anticoagulation	0.82 (0.55-1.28)	.230
Length of anticoagulation, mo	>6 versus ≤6	0.47 (0.26-0.88)	.018
Age, years	≤65 versus >65	0.87 (0.65-1.17)	.354
Primary treatment	Radiation alone versus surgery ± radiation	1.19 (0.88-1.59)	.260
No. of chemotherapy cycles	≥6 versus <6 cycles	0.62 (0.46-0.84)	.002
Gleason score	7 versus ≤6	1.37 (0.71-2.62)	.347
	8-10 versus ≤6	1.60 (0.85-3.00)	.144
No. of hormonal therapies	Continuous	0.94 (0.78-1.13)	.510
Bisphosphonate use	Yes versus no	0.86 (0.63-1.17)	.340
ECOG score	≥1 versus 0	1.60 (1.10-2.35)	.013
Hemoglobin (g/dL)	<12.0 versus ≥12.1	2.18 (1.63-2.94)	<.001
Albumin (U/L)	<4 versus ≥4	2.64 (1.66-4.22)	<.001
Alkaline phosphatase (U/L)	≥140 versus <140	1.72 (1.30-2.28)	<.001
AST or ALT elevation, or both (>40 U/L)	Yes versus no	2.45 (1.66-3.62)	<.001
Lymph node metastases	Yes versus no	0.96 (0.73-1.27)	.786
Visceral metastases	Yes versus no	1.98 (1.36-2.87)	<.001
Baseline (log) PSA	Continuous	1.11 (1.02-1.21)	.017

Bold values indicate statistically significant results.

Abbreviations: ALT = alanine aminotransferase; AST = aspartate aminotransferase; CI = confidence interval; ECOG = Eastern Cooperative Oncology Group; HR = hazard ratio; LMWH = low-molecular-weight heparin; PSA = prostate-specific antigen.